MX2022005639A - Compuestos inhibidores de pde-5 y/o pde-6 donadores de oxido de nitrogeno. - Google Patents

Compuestos inhibidores de pde-5 y/o pde-6 donadores de oxido de nitrogeno.

Info

Publication number
MX2022005639A
MX2022005639A MX2022005639A MX2022005639A MX2022005639A MX 2022005639 A MX2022005639 A MX 2022005639A MX 2022005639 A MX2022005639 A MX 2022005639A MX 2022005639 A MX2022005639 A MX 2022005639A MX 2022005639 A MX2022005639 A MX 2022005639A
Authority
MX
Mexico
Prior art keywords
pde
compounds
nitrogen oxide
donating
compositions
Prior art date
Application number
MX2022005639A
Other languages
English (en)
Inventor
Jeong-Ah Kim
Yoon-Suk Lee
Sung-Wook Kwon
Kyung-Sun Kim
Jeong-Geun Kim
An-Na Moon
Sun-Young Park
Jun-Su Ban
Dong-Keun Song
Ju-Young Jung
Soo-Jin Lee
Original Assignee
Ildong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ildong Pharmaceutical Co Ltd filed Critical Ildong Pharmaceutical Co Ltd
Publication of MX2022005639A publication Critical patent/MX2022005639A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente descripción proporciona compuestos inhibidores de fosfodiesterasa 5 (PDE-5) y/o fosfodiesterasa 6 (PDE-6) y composiciones que incluyen dichos compuestos. En algunas modalidades, dichos compuestos son compuestos inhibidores de PDE-5 y/o -6 donadores de óxido de nitrógeno (NO) que incluyen un sustituyente donador que contiene óxido de nitrógeno unido a un grup o bencenosulfonamida. Los compuestos pueden proporcionar una doble funcionalidad para aumentar la actividad de la proteína quinasa G (PKG) mediante la inhibición de PDE-5 y la PDE-6 y/o la estimulación de la guanilato ciclasa (sGC) mediante la donación de óxido de nitrógeno (NO) del sustituyente donador del compuesto. La presente descripción también proporciona métodos para usar dichos compuestos y composiciones para inhibir PDE -5 y/o -6 y aumentar la actividad de la proteína quinasa G (PKG). Los compuestos y composiciones encuentran uso en aplicaciones terapéuticas que incluyen el tratamiento de una variedad de enfermedades oculares. Por ejemplo, los compuestos en cuestión se pueden usar como agente terapéutico para el glaucoma, la degeneración macular relacionada con la edad (AMD), la retinopatía diabética (DR), la xeroftalmía, las cataratas o la uveítis.
MX2022005639A 2019-11-11 2020-11-09 Compuestos inhibidores de pde-5 y/o pde-6 donadores de oxido de nitrogeno. MX2022005639A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190143747A KR20210056827A (ko) 2019-11-11 2019-11-11 신규한 벤젠설폰아미드 유도체 및 그의 용도
PCT/IB2020/000950 WO2021094830A2 (en) 2019-11-11 2020-11-09 Nitrogen oxide-donating pde-5 and/or pde-6 inhibitor compounds

Publications (1)

Publication Number Publication Date
MX2022005639A true MX2022005639A (es) 2022-09-07

Family

ID=75911872

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005639A MX2022005639A (es) 2019-11-11 2020-11-09 Compuestos inhibidores de pde-5 y/o pde-6 donadores de oxido de nitrogeno.

Country Status (13)

Country Link
US (1) US20220380376A1 (es)
EP (1) EP4058457A4 (es)
JP (1) JP2023500947A (es)
KR (2) KR20210056827A (es)
CN (1) CN115038704A (es)
AU (1) AU2020382131A1 (es)
BR (1) BR112022009153A2 (es)
CA (1) CA3161134A1 (es)
CO (1) CO2022008136A2 (es)
IL (1) IL292900A (es)
MX (1) MX2022005639A (es)
TW (1) TW202132302A (es)
WO (1) WO2021094830A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR124014A1 (es) * 2020-11-09 2023-02-01 Ildong Pharmaceutical Co Ltd Compuestos inhibidores de la pde-5 y/o la pde-6 donantes de óxido de nitrógeno, y usos de estos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225315B1 (en) * 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
US6407259B1 (en) * 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
US20020168424A1 (en) * 2002-07-31 2002-11-14 Dr. Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for glaucoma
DE602004007840T2 (de) * 2003-03-18 2008-04-10 The Jordanian Pharmaceutical Manufacturing Co. Ltd. Pyrazolopyrimidinon und ihre Verwendung als PDE-Inhibitoren
NZ609955A (en) * 2010-11-09 2015-05-29 Ironwood Pharmaceuticals Inc Sgc stimulators
US8871781B2 (en) * 2011-11-30 2014-10-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating a subject for a lymphatic malformation
CN103374002B (zh) * 2012-04-19 2015-07-15 山东轩竹医药科技有限公司 磷酸二酯酶-5抑制剂
WO2015095515A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma
WO2015175704A1 (en) * 2014-05-14 2015-11-19 The Regents Of The University Of California Inhibitors of bacterial dna gyrase with efficacy against gram-negative bacteria
JP6867417B2 (ja) * 2016-06-21 2021-04-28 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤としてのｎ−（置換フェニル）−スルホンアミド誘導体

Also Published As

Publication number Publication date
EP4058457A4 (en) 2023-10-18
AU2020382131A1 (en) 2022-06-23
IL292900A (en) 2022-07-01
CO2022008136A2 (es) 2022-09-20
KR20210056827A (ko) 2021-05-20
CN115038704A (zh) 2022-09-09
KR20220101666A (ko) 2022-07-19
WO2021094830A3 (en) 2021-06-24
EP4058457A2 (en) 2022-09-21
WO2021094830A2 (en) 2021-05-20
TW202132302A (zh) 2021-09-01
JP2023500947A (ja) 2023-01-11
CA3161134A1 (en) 2021-05-20
BR112022009153A2 (pt) 2022-07-26
US20220380376A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
WO2016134223A3 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
PH12019500932A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
SG11201806930PA (en) Novel condensed pyrimidine compound or salt thereof
MX2020014163A (es) Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo [1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.
WO2018155916A3 (ko) 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
MX2022010011A (es) Inhibidores de prmt5 novedosos.
WO2008106692B1 (en) Pim kinase inhibitors and methods of their use
PH12016501357B1 (en) Pharmaceutical preparation containing pyridylaminoacetic acid compound
MX2015008396A (es) Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.
MX2022008881A (es) Compuesto heterociclico de pirimidin-4(3h)-ona, metodo de preparacion del mismo y su uso farmaceutico.
WO2007046083A3 (en) Compositions for treatment of eye diseases
JOP20220131A1 (ar) مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة
MA38315A1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
EA201990235A1 (ru) ТВЕРДЫЕ ФОРМЫ СТИМУЛЯТОРА sGC
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
WO2009041566A1 (ja) キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤
ZA202204666B (en) 2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors
WO2018089328A8 (en) TREATMENT OF CNS DISEASES USING GCS STIMULATORS
WO2018089330A3 (en) Sgc stimulators
MX2022005639A (es) Compuestos inhibidores de pde-5 y/o pde-6 donadores de oxido de nitrogeno.
PH12021551035A1 (en) Pyrazoles as modulators of hemoglobin
WO2022096930A3 (en) Nitrogen oxide-donating pde-5 and/or pde-6 inhibitor compounds, and uses thereof